# ARHGEF9

## Overview
The ARHGEF9 gene encodes the protein collybistin, a member of the Dbl family of guanine nucleotide exchange factors, which plays a pivotal role in synaptic organization within the brain. Collybistin is characterized by its multi-domain structure, including a Src homology 3 (SH3) domain, a Dbl homology (DH) domain, and a pleckstrin homology (PH) domain, which facilitate its interactions with various synaptic proteins and lipids (Long2016Missense; Yao2020Clinical). As a Cdc42-specific guanine nucleotide exchange factor, collybistin is involved in the activation of Cdc42, a small GTPase critical for cytoskeletal organization and cell signaling (Simon2015Interkingdom). The protein is predominantly expressed in the brain, where it is essential for the clustering of gephyrin-dependent glycine receptors and GABA A receptors at inhibitory postsynaptic sites, thereby maintaining synaptic plasticity and cognitive functions (Yao2020Clinical). Mutations in ARHGEF9 are linked to various neurological disorders, including epilepsy, intellectual disability, and autism spectrum disorder, underscoring its clinical significance (Marco2007ARHGEF9; Wang2017ARHGEF9).

## Structure
The ARHGEF9 gene encodes the protein collybistin, which is a member of the Dbl family of guanine nucleotide exchange factors. Collybistin has a multi-domain structure that includes a Src homology 3 (SH3) domain, a Dbl homology (DH) domain, and a pleckstrin homology (PH) domain (Long2016Missense; Yao2020Clinical). The SH3 domain is involved in interactions with neuroligin-2 and the α2 subunit of GABA A receptors, playing a role in synaptic organization (Hines2022Human). The DH domain is crucial for the protein's function, interacting with other residues through hydrogen bonds, and is associated with epilepsy when mutated (Wang2017ARHGEF9). The PH domain is responsible for binding phosphatidylinositol-3-phosphate (PI 3 P), which is important for membrane interaction and gephyrin clustering (Long2016Missense; Wang2017ARHGEF9).

Collybistin is predominantly expressed in the brain and is involved in the clustering of gephyrin-dependent glycine receptors and GABA A receptors at inhibitory postsynaptic sites (Yao2020Clinical). The protein occurs in multiple splice variants, although specific isoforms are not detailed in the provided context (Long2016Missense).

## Function
The ARHGEF9 gene encodes the protein collybistin, which is crucial for synaptic function in the brain. Collybistin facilitates the clustering of gephyrin-dependent glycine receptors and γ-aminobutyric acid type A (GABAα) receptors at inhibitory postsynaptic sites, a process essential for proper neurotransmission (Yao2020Clinical). The protein is composed of an SH3 domain, DH domain, and PH domain, which enable its attachment to the membrane and interaction with other proteins. The SH3 domain binds to the membrane-integral neuroligin-2 protein, while the PH domain interacts with PI3P, and the DH domain is critical for binding gephyrin, a scaffolding protein that anchors receptors to the postsynaptic cytoskeleton (Yao2020Clinical).

ARHGEF9 is predominantly expressed in the brain, where it plays a significant role in maintaining synaptic plasticity and cognitive functions. Disruption of ARHGEF9 can lead to altered synaptic plasticity and various neurological disorders, including epilepsy and intellectual disability (Yao2020Clinical). Additionally, ARHGEF9 acts as a Cdc42-specific guanine nucleotide exchange factor, promoting the activation of Cdc42, which is involved in cytoskeletal organization and cell signaling (Simon2015Interkingdom). This activation is crucial for processes such as cell migration and synaptic function (Simon2015Interkingdom).

## Clinical Significance
Mutations in the ARHGEF9 gene, which encodes the protein collybistin, are associated with a range of neurological disorders. These include epileptic encephalopathy, intellectual disability, autism spectrum disorder (ASD), and sensory hyperarousal. The gene is located on the X chromosome, and its mutations often lead to X-linked disorders (Marco2007ARHGEF9; Wang2017ARHGEF9).

In males, ARHGEF9 mutations can result in severe intellectual disability, developmental delay, seizures, and ASD. The severity of these conditions is influenced by the specific mutation type and its location within the gene (Aarabi2019Autism; Wang2017ARHGEF9). In females, the clinical presentation is more variable, often due to random patterns of X chromosome inactivation, which can lead to a range of symptoms from mild to severe (Aarabi2019Autism; Ghesh2021Loss‐of‐function).

The ARHGEF9 gene is crucial for synaptic function, and its mutations disrupt the clustering of gephyrin and GABA A receptors at inhibitory synapses, leading to impaired synaptic transmission. This disruption is a key factor in the development of the associated neurological disorders (Yao2020Clinical; Bhat2016Xq11.111.2).

## Interactions
The ARHGEF9 gene encodes the protein collybistin, which is a guanine nucleotide exchange factor involved in synaptic organization. Collybistin interacts with several proteins, playing a crucial role in the regulation of inhibitory synapse function. It interacts with the adhesion molecule neuroligin-2 (NL2) through its Src homology (SH) 3 domain, and with the α2 subunit of GABA A receptors via 13 amino acids within the large intracellular loop of the α2 subunit. This interaction is essential for the proper functioning of inhibitory synapses (Hines2022Human).

Collybistin also interacts with gephyrin, another synaptic organizer, which has a stronger interaction with the α1/3 subunits of GABA A receptors but weaker binding with the α2 subunit. The α1 and α2 subunits are localized differently within inhibitory synapse subtypes, with α1 being enriched at dendritic inhibitory synapses and somatic synapses from parvalbumin-positive basket cells, while α2 is enriched at somatic synapses from cholecystokinin-positive basket cells and axon initial segment synapses from chandelier cells (Hines2022Human).

Mutations in ARHGEF9 that disrupt collybistin binding to the GABA A receptor α2 subunit lead to downregulation of collybistin expression and are associated with intellectual disability syndromes, highlighting the importance of these interactions in maintaining synaptic stability and function (Hines2022Human).


## References


[1. (Long2016Missense) Philip Long, Melanie M. May, Victoria M. James, Simone Grannò, John P. Johnson, Patrick Tarpey, Roger E. Stevenson, Kirsten Harvey, Charles E. Schwartz, and Robert J. Harvey. Missense mutation r338w in arhgef9 in a family with x-linked intellectual disability with variable macrocephaly and macro-orchidism. Frontiers in Molecular Neuroscience, January 2016. URL: http://dx.doi.org/10.3389/fnmol.2015.00083, doi:10.3389/fnmol.2015.00083. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnmol.2015.00083)

[2. (Aarabi2019Autism) Mahmoud Aarabi, Elena Kessler, Suneeta Madan-Khetarpal, Urvashi Surti, Daniel Bellissimo, Aleksandar Rajkovic, and Svetlana A. Yatsenko. Autism spectrum disorder in females with arhgef9 alterations and a random pattern of x chromosome inactivation. European Journal of Medical Genetics, 62(4):239–242, April 2019. URL: http://dx.doi.org/10.1016/j.ejmg.2018.07.021, doi:10.1016/j.ejmg.2018.07.021. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ejmg.2018.07.021)

[3. (Hines2022Human) Dustin J. Hines, April Contreras, Betsua Garcia, Jeffrey S. Barker, Austin J. Boren, Christelle Moufawad El Achkar, Stephen J. Moss, and Rochelle M. Hines. Human arhgef9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the gabaa receptor α2 subunit. Molecular Psychiatry, 27(3):1729–1741, February 2022. URL: http://dx.doi.org/10.1038/s41380-022-01468-z, doi:10.1038/s41380-022-01468-z. This article has 7 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41380-022-01468-z)

[4. (Marco2007ARHGEF9) E J Marco, F E Abidi, J Bristow, W B Dean, P Cotter, R J Jeremy, C E Schwartz, and E H Sherr. Arhgef9 disruption in a female patient is associated with x linked mental retardation and sensory hyperarousal. Journal of Medical Genetics, 45(2):100–105, September 2007. URL: http://dx.doi.org/10.1136/jmg.2007.052324, doi:10.1136/jmg.2007.052324. This article has 56 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmg.2007.052324)

[5. (Simon2015Interkingdom) Sylvia Simon, Ursula Schell, Natalie Heuer, Dominik Hager, Michael F. Albers, Jan Matthias, Felix Fahrnbauer, Dirk Trauner, Ludwig Eichinger, Christian Hedberg, and Hubert Hilbi. Inter-kingdom signaling by the legionella quorum sensing molecule lai-1 modulates cell migration through an iqgap1-cdc42-arhgef9-dependent pathway. PLOS Pathogens, 11(12):e1005307, December 2015. URL: http://dx.doi.org/10.1371/journal.ppat.1005307, doi:10.1371/journal.ppat.1005307. This article has 39 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.ppat.1005307)

[6. (Yao2020Clinical) Ruen Yao, Yi Zhang, Jie Liu, Jiwen Wang, Yufei Xu, Niu Li, Jian Wang, and Tingting Yu. Clinical and molecular characterization of three novel arhgef9 mutations in patients with developmental delay and epilepsy. Journal of Molecular Neuroscience, 70(6):908–915, January 2020. URL: http://dx.doi.org/10.1007/s12031-019-01465-y, doi:10.1007/s12031-019-01465-y. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12031-019-01465-y)

[7. (Bhat2016Xq11.111.2) Gifty Bhat, Danielle LaGrave, Alison Millson, John Herriges, Allen N. Lamb, and Reuben Matalon. Xq11.1-11.2 deletion involving arhgef9 in a girl with autism spectrum disorder. European Journal of Medical Genetics, 59(9):470–473, September 2016. URL: http://dx.doi.org/10.1016/j.ejmg.2016.05.014, doi:10.1016/j.ejmg.2016.05.014. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ejmg.2016.05.014)

[8. (Ghesh2021Loss‐of‐function) Leïla Ghesh, Thomas Besnard, Mathilde Nizon, Eva Trochu, Gaëlle Landeau‐Trottier, Flora Breheret, Christel Thauvin‐Robinet, Ange‐Line Bruel, Paul Kuentz, Christine Coubes, Laurence Cuisset, Cyril Mignot, Boris Keren, Stéphane Bézieau, and Benjamin Cogné. Loss‐of‐function variants in arhgef9 are associated with an x‐linked intellectual disability dominant disorder. Human Mutation, 42(5):498–505, March 2021. URL: http://dx.doi.org/10.1002/humu.24188, doi:10.1002/humu.24188. This article has 1 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.24188)

[9. (Wang2017ARHGEF9) Jing-Yang Wang, Peng Zhou, Jie Wang, Bin Tang, Tao Su, Xiao-Rong Liu, Bing-Mei Li, Heng Meng, Yi-Wu Shi, Yong-Hong Yi, Na He, and Wei-Ping Liao. Arhgef9 mutations in epileptic encephalopathy/intellectual disability: toward understanding the mechanism underlying phenotypic variation. neurogenetics, 19(1):9–16, November 2017. URL: http://dx.doi.org/10.1007/s10048-017-0528-2, doi:10.1007/s10048-017-0528-2. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10048-017-0528-2)